Led ALP Bio AG's $2.2M pre-seed round to de-risk antibody development with immunogenicity intelligence.
ALP Bio is developing an immune organoid and AI platform for immunogenicity intelligence in biologics development
ALP Bio is developing an immune organoid and AI platform for immunogenicity intelligence in biologics development. The company combines human immune organoid readouts with generative AI to help drug developers predict and reduce anti-drug antibody risk earlier in antibody discovery and development.